NCT00152282View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

August 31, 2001

Study Completion Date

August 31, 2001

Conditions
AmenorrheaPostmenopause
Interventions
DRUG

Asoprisnil/Premarin

Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks

DRUG

Asoprisnil/Premarin

Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks

DRUG

Asoprisnil/Premarin

Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks

DRUG

Placebo and Premarin

Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY